美国外科病理学杂志09年4月 第3篇.pdfVIP

ORIGINAL ARTICLE CD3-positive Large B-cell Lymphoma Jun Wang, MD,* Chen Chen, MD, PhD,w Sean Lau, MD,z Ravi I. Raghavan, MD,* Edward H. Rowsell, MD, PhD,* Jonathan Said, MD,w Lawrence M. Weiss, MD,z and Qin Huang, MD, PhDz neoplasm. Thus, immunohistochemistry using additional Abstract: It is not uncommon for some B-lineage non-Hodgkin cell lineage-specific markers or molecular analysis for lymphomas (NHLs) to aberrantly coexpress T-cell markers, antigen-receptor gene rearrangements are necessary for particularly CD5, as well as CD7, CD2, CD4, and/or CD8 in correct determination of the cell lineage in such unusual rare cases. Cases of CD3-positive B-cell NHL, however, have lesions. not previously been described in the literature. We present 4 cases of large B-cell lymphoma aberrantly coexpressing T-cell marker CD3 and B-lineage markers as well as demonstrating MATERIALS AND METHODS clonal rearrangement of the immunoglobulin genes but not the g T-cell receptor gene. To our knowledge, this represents the first Case Selection series report of B-cell NHL coexpressing T-lineage–specific All 4 cases selected based on aberrantly expressed T- marker CD3. The identification of such cases indicates that the cell marker CD3 expressed at least 1 of B-cell–specific or use of CD3 antibody alone in paraffin sections may lead to an related marker CD20, PAX5, CD79a, and/or CD138. incorrect determination of cell lineage in some B-cell NHL. One case (case 1) was seen as a brain tumor at Loma Immunohistochemistry using a